** Shares of Maze Therapeutics MAZE.O rise 4.8% to $11.34
** Wall Street brokerages start coverage of the drug developer on a bullish note as IPO research quiet period ends
** J.P. Morgan starts coverage with "overweight" rating and $30 PT, a 177.2% upside to the stock's last close
** "With data for MZE829 available, we see its potential in addressing a wide population, competitive pricing, market share, and high success probability as key factors for boosting MAZE shares" - J.P. Morgan analysts referring to co's kidney disease therapy candidate
** Leerink Partners starts coverage with "outperform" rating and PT of $28, a 158.8% upside to the stock's last close
** "Chronic kidney disease represents a significant market opportunity, especially considering the major drain on overall Medicare spending. We assume gross peak sales of ~$1.8B in CKD" - Leerink Partners
** J.P. Morgan, TD Cowen, Leerink Partners and Guggenheim Securities were the underwriters for the IPO
** Stock has fallen 32% since its Nasdaq debut in January
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。